CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
The Lancet. Haematology（2023）
Abstract
Celyad Oncology.
MoreTranslated text
Key words
refractory acute myeloid leukaemia,myelodysplastic syndromes,multiple myeloma,d-based,t-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined